

CURRICULUM VITAE

Date of Revision: August 17, 2021

Name: Sarah B. Goldberg, MD, MPH

Position: Associate Professor
Clinician-Scientist Track
Department of Internal Medicine, Section of Medical Oncology

Term: July 1, 2019 – June 30, 2024

School: Yale University School of Medicine

Education:
B.S. Tufts University (Biology) 2001
M.D. Mount Sinai School of Medicine 2006
M.P.H. Harvard University (Clinical Effectiveness) 2012

Career/Academic Appointments:
2006-07 Intern, Internal Medicine, Massachusetts General Hospital, Boston, MA
2007-09 Resident, Internal Medicine, Massachusetts General Hospital, Boston, MA
2009-12 Fellow in Hematology/Oncology, Dana-Farber/Harvard Cancer Center, Boston, MA
2012-2019 Assistant Professor of Medicine, Dept. of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT
2019-present Associate Professor of Medicine, Dept. of Medicine (Medical Oncology), Yale University School of Medicine, New Haven, CT

Administrative Positions:
2021-present Research Director, Yale Thoracic Oncology, New Haven, CT
2020-present Associate Program Director, Yale Medical Oncology/Hematology Fellowship, New Haven, CT

Board Certification:
American Board of Internal Medicine, Internal Medicine, 2009
American Board of Internal Medicine, Medical Oncology, 2012

Professional Honors & Recognition:

International/National/Regional
2020: The David S. Fischer, MD Annual Award for Outstanding Teaching and Mentoring of Fellows in Medical Oncology
2013: SWOG/The Hope Foundation Young Investigator
2012-2018: Clinical Research Loan Repayment Program Award, National Institutes of Health
2006: Alpha Omega Alpha, Mount Sinai School of Medicine
2006: Gold Humanism Honor Society, Mount Sinai School of Medicine

2006: The Dr. John J. Bookman Memorial Prize for excellence in academic achievement
2001: Magna Cum Laude, Tufts University
2000: Golden Key National Honor Society, Tufts University

Grant History:

Current Grants

Agency: NIH/NCI
ID#: P50 CA196530-01
Title: Yale SPORE in Lung Cancer (YSILC): Project #2 Targeting the EGF Receptor Pathway in Lung Adenocarcinoma
P.I.: Roy Herbst, MD PhD
Role: Project 2 Co-Leader
Project Period: 8/1/2020-7/31/2025

Agency: NIH/NCI
ID#: P50CA196530
Title: Yale SPORE in Lung Cancer (YSILC): Project #3 Molecular Determinants of Lung Cancer Metastasis and Drug Response in the CNS
PI: Roy Herbst, MD PhD
Role: Project 3 Co-investigator
Project Period: 8/1/2020-7/31/2025

Agency: Astra-Zeneca
ID#: N/A
Title: *Effects of Concurrent Chemoradiation on the Immune Microenvironment in Stage III NSCLC*
Role: PI
Project Period: 09/01/2020-08/31/2023

Agency: NIH/NCI
ID#: R01 CA166376-01A1
Title: Characterizing a novel lineage specific metastasis pathway in lung cancer
PI: Don Nguyen, PhD
Role: Co-investigator
Project Period: 9/1/19-8/31/24

Agency: NIH/NCI
ID#: 1R01EB025468-01A1
Title: Quantitative Low-dose PET Imaging
P.I.: Chi Liu, PhD and Richard Carson, PhD
Role: Co-investigator
Project Period: 07/24/18-04/30/22

Agency: NIH/NCI
ID#: 1R01CA224140-01A1

Title: Personalized Task-based respiratory motion correction for low-dose PET/CT
P.I.: Chi Liu, PhD and M Casey, PhD
Role: Co-investigator
Project Period: 07/02/18-06/30/23

Agency: SWOG
ID#: N/A
Title: A Randomized Phase II/III Trial of Afatinib Plus Cetuximab Versus Afatinib Alone in Treatment Naïve Patients with Advanced, EGFR Mutation Positive Non-Small Cell Lung Cancer
PI: Katerina Politi, PhD
Role: Co-PI
Project Period: 04/01/2015-6/30/2020 (in NCE)

Past Grants

Agency: NIH/NCI
ID#: 5R01CA197486-03
Title: Circulating DNA as a Marker of Treatment Efficacy and Failure in Lung Cancer
PI: Abijit Patel, PhD
Role: Co-investigator
Project Period: 4/1/16 – 3/31/21

Agency: Boehringer Ingelheim
ID#: N/A
Title: Afatinib for patients with uncommon exon 19 deletion EGFR mutations
Role: PI
Project Period: 11/1/2019-10/31/2020

Agency: NCI
ID#: 15X147TO2
Title: Predictors of benefit from osimertinib with or without bevacizumab in patients with EGFR mutant lung cancer and brain metastases
Role: PI
Project Period: 11/2/18-11/1/21

Agency: NIH/NCI
ID#: P50 CA196530-01
Title: Yale SPORE in Lung Cancer (YSILC): Project #3 Targeting the EGF Receptor Pathway in Lung Adenocarcinoma
P.I.: Roy Herbst, MD PhD
Role: Project 3 Co-Leader
Project Period: 08/26/2015-07/31/2020

Agency: NIH/NCI
ID#: P50CA196530

Title: Yale SPORE in Lung Cancer (YSILC): Project #5 Molecular determinants of lung cancer metastasis and drug response in the CNS
PI: Don Nguyen, PhD
Role: Project 5 Co-investigator
Project Period: 8/1/18-7/31/20

Agency: Department of Defense Lung Cancer Research Program
ID#: Career Development Award
Title: Evaluation of biomarkers predictive of benefit from the PD-1 inhibitor pembrolizumab in patients with non-small cell lung cancer and brain metastases
Role: PI
Project Period: 7/1/15-6/30/17, 7/1/17-6/30/18 in NCE

Agency: NIH/NCI
ID#: 5R01CA195493-03
Title: Validation of Quantitative 11C-Erlotinib PET for Imaging EGFR-Mutant Lung Cancer
PI: Evan Morris, PhD
Role: Co-investigator
Project Period: 5/19/15 – 04/30/2018 (05/01/2018 – 04/30/2020 in NCE)

Agency: NIH/NCI
ID#: 1UM1CA186689-01
Title: ViKTriY Early Clinical Trials Consortium (ECTC)
PI: Patricia LoRusso, M.D.
Project Period: 07/09/2014–07/31/2019

Agency: The Hope Foundation
ID#: Career Development Award
Title: A Phase II/III randomized trial of afatinib with or without cetuximab in treatment-naïve patients with advanced EGFR-mutant non-small cell lung cancer.
Role: PI
Project Period: 12/01/2014-06/30/2016

Agency: AstraZeneca
ID#: Industry Grant
Title: Evaluation and identification of biomarkers in non-small cell lung cancer.
Role: PI
Project Period: 11/13/2013 – 11/12/2015 (11/13/15 - 05/14/16 in NCE)

Agency: AstraZeneca
ID#: Industry Grant
Title: Evaluation and identification of MEK-related biomarkers in non-small cell lung cancer.
Role: PI
Project Period: 12/18/2013 – 12/17/2015 (05/18/2016 – 12/17/2016 in NCE)

Agency: Yale Cancer Center for Clinical Investigation

ID#: Core Pilot
Title: 11C-erlotinib PET Imaging in Non-Human Primates
Role: Co-PI
Project Period: 1/1/14-6/30/14

Invited Speaking Engagements, Presentations, Symposia & Workshops Not Affiliated with Yale
International/National

- 2021: University of Oklahoma Heme-Onc Grand Rounds “Advances in the Management of Lung Cancer Brain Metastases”
- 2021: Society for Immunotherapy of Cancer (SITC), Combination Immunotherapy Resistance Workshop
- 2021: 18th Annual Winter Lung Cancer Conference, Miami, FL. “When to Stop Immunotherapy”
- 2020: Society for Immunotherapy of Cancer (SITC) Advances in Cancer Immunotherapy™ (ACI) regional series, “Immunotherapy for the Treatment of Lung Cancer (NSCLC and SCLC)”
- 2020: 21th Annual International Lung Cancer Congress, Huntington Beach, CA, “Managing Patients with BRAF-mutant NSCLC” and “Overcoming Mechanisms of Acquired Resistance in Oncogene-Driven Lung Cancer”
- 2020: IASLC Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA. “Oleclumab”
- 2019: 20th Annual International Lung Cancer Congress, Huntington Beach, CA, “Combining Immunotherapy With Targeted Agents” and “Overcoming Mechanisms of Acquired Resistance in Oncogene-Driven Lung Cancer”
- 2019: Multidisciplinary Thoracic Cancers Symposium, San Diego, CA. “Immunotherapy and Brain Metastases”
- 2019: IASLC Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA. “Osimertinib + CD73 Ab”
- 2019: 16th Annual Winter Lung Cancer Conference, Miami, FL. “Managing CNS Disease in Oncogene-Driven NSCLC” and “Emerging Approaches for Mesothelioma”
- 2018: World Conference on Lung Cancer, Toronto, Canada. “Can I treat brain metastasis with immunotherapy?”
- 2018: Medical Learning Institute and PeerView, San Antonio, TX. “The Era of Immunotherapy in Stage III NSCLC: Exploring the Evidence and Practicalities of Integrating Checkpoint Inhibition into the Multimodal Treatment Arsenal”

- 2018: 19th Annual International Lung Cancer Congress, Huntington Beach, CA, “Combining Immunotherapy With Targeted Agents” and “Overcoming Mechanisms of Acquired Resistance in Oncogene-Driven Lung Cancer”
- 2018: ASCO Annual Meeting, Chicago, IL: Discussant for Poster Discussion Session. “Optimizing the Use of Immunotherapy”
- 2018: 5th Annual Miami Lung Cancer Conference: Miami, FL “How to Test for and Treat Resistance to EGFR TKI Therapy”
- 2018: 18th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA. “IO + CD73” and “Afatinib + Dasatinib or Cetuximab”
- 2017: 4th Annual Miami Lung Cancer Conference, Miami, FL. “How I Treat Advanced NSCLC Without Actionable Oncogenic Drivers”
- 2017: 18th Annual International Lung Cancer Congress, Huntington Beach, CA “Sequencing EGFR TKI Therapy in 2017” and “Overcoming Mechanisms of Acquired Resistance in Oncogene-Driven Lung Cancer”
- 2017: WCIO 2017, Boston, MA. “Will Personalized Medicine Replace the Role of Intervention?”
- 2017: 15th Annual Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA. “Pembrolizumab for NSCLC Brain Metastases.”
- 2016: 3rd Annual Miami Lung Cancer Conference, Miami, FL. “A Changed Immunotherapy Landscape in NSCLC: How Do the Data Compare?”
- 2015: Best of ASCO 2015, Boston, MA. “Non-small cell lung cancer Local-Regional/Small Cell/Other Thoracic Cancers”
- 2015: 2nd Annual Miami Lung Cancer Conference, “PD-(L)1 inhibitors: Activity as Single Agents, Potential Biomarkers
- 2015: 15th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, CA “Medi 4736/Tremelumimab”, “Pembrolizumab in Brain Metastases” and “Afatinib in HER2-mutant NSCLC”
- 2014: 2nd Annual Summit on Practical and Emerging Approaches for Lung Cancer, Dallas, TX. “Targeting PD-L1 in lung cancer”
- 2014: Regional Summit on Practical and Emerging Trends in Lung Cancer. New York, NY. “Nivolumab and checkpoint inhibitors in NSCLC”
- 2014: Seventh Annual Symposium on Personalized Therapies and Best Clinical Practices for Lung

Cancer, San Francisco, CA. “Checkpoint inhibition in first-line therapy for patients with advanced lung cancer.”

- 2014: 1st Annual Summit on Practical and Emerging Agents in Lung Cancer, Miami Beach, FL. “EGFR and ALK-targeted therapies in NSCLC”
- 2014: IASLC Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA. “Afatinib in HER2-mutant NSCLC.
- 2014: Best of ASCO 2014, Boston, MA. “Non-small cell lung cancer Local-Regional/Small Cell/Other Thoracic Cancers”
- 2013: Summit on Practical and Emerging Approaches for Lung Cancer, Dallas, TX. “Mechanisms of Resistance to EGFR TKIs: Pathways to Progress in EGFRmut NSCLC”
- 2013: 5th International Congress on Personalized Therapy for Non-Small-Cell Lung Cancer and Head & Neck Cancer, Philadelphia, PA. “Current CALGB and SWOG Clinical Trials”
- 2013: IASLC Targeted Therapies of Lung Cancer Meeting, Santa Monica, CA. “Afatinib in HER2-mutant NSCLC.”
- 2012: Novel Agents in Lung Cancer, Cambridge, MA. “Afatinib plus cetuximab in non-small cell lung cancer.”

Regional

- 2018: Chemotherapy Foundation, New York, NY. “EGFR-mutated lung cancer: Frontline strategies and beyond.”
- 2017: ImmunoOncology Forum III: Focus on NSCLC, New York, New York "Toward an Individualized Approach to NSCLC Management: The Impact of Molecular Profiling.”
- 2016: Chemotherapy Foundation, New York, NY. “PD-L1 as a Biomarker: Can we Optimize or Are There Better Options?”
- 2016: Grand Rounds, Brookdale Hospital, New York, NY. “Changing the Landscape of Lung Cancer Treatment with Targeted and Immune Therapy.”

Media

- 2021: OncLive, Advances in Immunotherapy in Metastatic NSCLC: An OncLive Scientific Interchange and Exchange
- 2021: Targeted Oncology, Co-moderator - Virtual Case-Based Roundtable Meeting on NSCLC / Metastatic NSCLC
- 2016: IASLC webinar series-Lung Cancer Grand Rounds, “Emerging Therapy Options in Immunotherapy for Non-Small Cell Lung Cancer”

2015: Research to Practice, Interview with Dr. Neil Love, “Lung Cancer Update”

2014: CancerCare Connect Education Workshop. “Advances in the Treatment of Lung Cancer.”

2013: WNPR Radio Program, “Lung Cancer Research.”

Professional Service

Peer Review Groups/Grant Study Sections:

- 2020 Ad Hoc Reviewer, National Comprehensive Cancer Network (NCCN) Young Investigator Award
- 2019 Ad Hoc Reviewer, Lung Cancer Research Foundation
- 2016-2020 Ad Hoc Reviewer, U.S. Army Medical Research and Materiel Command, Congressionally Directed Medical Research Programs (CDMRP), Lung Cancer Research Program (LCRP)

Advisory Boards:

- 2020 Scientific Advisory Board Member, Sanofi-Genzyme
- 2020 Scientific Advisory Board Member, Daiichi-Sankyo
- 2020 Scientific Advisory Board Member, Blueprint Medicine
- 2020 Publication Steering Committee Member for Cemiplimab
- 2018-present Steering Committee Member, AstraZeneca, A Phase 2a, Open-Label, Multicentre, Umbrella Study in EGFR mutation positive locally advanced or metastatic Non-Small Cell Lung Cancer Patients, who have progressed on osimertinib first line therapy, to Assess the Safety, Tolerability, and Efficacy of Investigational Agents, either as Monotherapy or in Combination (ORCHARD)
- 2018 Scientific Advisory Board Member, Amgen
- 2018 Scientific Advisory Board Member, Spectrum
- 2018-present Scientific Advisory Board Member, Genentech
- 2018 Scientific Advisory Board Chair, AstraZeneca
- 2017-present Scientific Advisory Board Member, AstraZeneca
- 2017 Lead Scientific Advisory Board Member, Boehringer Ingelheim
- 2017 Scientific Advisory Board Member, Eli Lilly
- 2017-present Scientific Advisory Board Member, Bristol-Myers Squibb
- 2016 Metastatic Cancer Task Force Operational Meeting, Department of Defense
- 2015-present Steering Committee Member, MedImmune, A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination with Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients with Advanced or Metastatic Non-Small- Cell Lung Cancer (NSCLC) (MYSTIC)
- 2014 Scientific Advisory Board Member, Clovis
- 2013 Scientific Advisory Board Member, Boehringer Ingelheim

Journal Service:

Editor/Associate Editor

2017-present Associate Editor, *Cancer Treatment and Research Communications*

Reviewer

2020-present Reviewer for *Translational Lung Cancer Research*
2020-present Reviewer for *Journal for ImmunoTherapy of Cancer*
2020-present Reviewer for *Nature Cancer*
2019-present Reviewer for *Lancet*
2017-present Reviewer for *Clinical Cancer Research*
2015-present Reviewer for *Journal of Clinical Oncology*
2013-present Reviewer for *The Oncologist*
2013-present Reviewer for *Lung Cancer*
2013-present Reviewer for *Clinical Lung Cancer*
2013-present Reviewer for *BMC Cancer*

Professional Service for Professional Organizations

PracticeUpdate Oncology

2020-present Associate Editor
2019-2020 Member, Advisory Board

Southwest Oncology Group

2012-present Member, Thoracic Working Group

International Association for the Study of Lung Cancer

2018-2019 Member, Education Committee
2010-present Member

American Society of Clinical Oncology

2009-present Member
2021-2024 Research Committee

Meeting Planning/Participation

2021 World Conference on Lung Cancer 2021 Program Committee, Liquid Biopsy and Other Non-invasive Diagnostic Modalities track
2021 Society for Neuro-Oncology (SNO)/ American Society of Clinical Oncology (ASCO), Planning Committee for the Annual Conference on CNS Clinical Trials
2020 Track Co-Chair, World Conference on Lung Cancer 2020 Program Committee
2018 World Conference on Lung Cancer, Abstract Selection Committee

Yale University Service

University Committees

2021 Scholar Selection Committee, Yale Center for Clinical Investigation
2020 Member, Clinical Trials Advisory Committee

2020	Member, COVID-19 Clinical Trials Subcommittee
2020	Reviewer, Yale Medical School Thesis Committee
2016-2019	Member, Ambulatory Care Committee
2014-2018	Member, Data Safety Monitoring Committee
2014, 2019	Participation on the PA Thesis Readers Committee

Departmental Committees

2020	Reviewer, V Foundation (internal candidate review)
2020	Reviewer, NCI-COVID19 supplemental funding through the Yale Cancer Center
2020	Member, Communication Culture and Engagement Task Force
2017	Medical Oncology Retreat Planning Committee
2017	Clinical Trials Office 2020, Taskforce Member
2015	Compensation Committee Member
2013-present	Co-director, Lung Cancer Case Conference

Public Service:

2018	Lung Cancer Living Room
2012-present	Speaker at the Yale Lung Cancer Awareness Month Event

Bibliography:

Peer-Reviewed Original Research

1. T.J. Moscarillo, H. Holt, M. Perman, **S. Goldberg**, L.Cortellini, J.M. Stoler, W. DeJong, B.J. Miles, M.S. Albert, R.C. Go, D. Blacker. Knowledge of and Attitudes about Alzheimer Disease Genetics: Report of a Pilot Survey and Two Focus Groups. *Community Genet* 2007, 10(2):97-102.
2. J.S. Temel, J.A. Greer, **Goldberg S**, P.D. Vogel, M. Sullivan, W.F. Pirl, T.J. Lynch, D.C. Christiani, M.R. Smith. A Structured Exercise Program for Patients with Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology* 2009, 4(5):595-601.
3. L.V. Sequist, R.S. Heist, A.T. Shaw, P. Fidias, R. Rosovsky, J.S. Temel, I.T. Lennes, S. Digumarthy, B.A. Waltman, E. Bast, S. Tammireddy, L. Morrissey, A. Muzikansky, **S.B. Goldberg**, J. Gainor, C.L. Channick, J.C. Wain, H. Gaissert, D.M. Donahue, A. Muniappan, C. Wright, H. Willers, D.J. Mathisen, N.C. Choi, J. Baselga, T.J. Lynch, L.W. Ellisen, M. Mino-Kenudson, M. Lanuti, D.R. Borger, A.J. Iafrate, J.A. Engelman, D. Dias-Santagata. Implementing Multiplexed Genotyping of Non-Small Cell Lung Cancers into Routine Clinical Practice. *Annals of Oncology* 2011;22(12):2616-2624.
4. **Goldberg SB**, Supko JG, Neal JW, Muzikansky A, Digumarthy A, Fidias P, Temel JS, Heist RS, Shaw AT, McCarthy PO, Lynch TJ, Sharma S, Settleman JE, Sequist LV. A Phase I Study of Erlotinib and Hydroxychloroquine in Advanced Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology* 2012;7(10):1602-8.
5. Johung KL, Yao X, Li F, Yu JB, Gettinger SN, **Goldberg S**, Decker RH, Hess JA, Chiang VL, Contessa JN. A Clinical Model for Identifying Radiosensitive Tumor Genotypes in Non-Small Cell Lung Cancer. *Clin Cancer Res.* 2013; 19(19):5523-32.

6. **Goldberg SB**, Oxnard GR, Digumarthy S, Muzikansky A, Jackman DM, Lennes IT, Sequist LV. Chemotherapy with erlotinib or chemotherapy alone in advanced non-small cell lung cancer with acquired resistance to EGFR tyrosine kinase inhibitors. *Oncologist*. 2013; 18(11):1214-20. doi: 10.1634/theoncologist.2013-0168. Epub 2013 Sep 26. PMID:24072220
7. Boffa DJ, Hancock JG, Yao X, **Goldberg SB**, Rosen JE, Kim AW, Moreno A, Detterbeck FC. Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database. *Ann Thorac Surg*. 2015 Jan;99(1):200-8. PMID: 25440272
8. Johung KL, Yeh N, Desai NB, Williams TM, Lautenschlaeger T, Arvold ND, Ning MS, Attia A, Lovly CM, **Goldberg S**, Beal K, Yu JB, Kavanagh BD, Chiang VL, Camidge DR, Contessa JN. Extended Survival and Prognostic Factors for Patients with ALK Rearranged NSCLC and Brain Metastasis. *J Clin Oncol*. 2016 Jan 10;34(2):123-9.
9. Antonia S*, **Goldberg SB***, Balmanoukian A, et al. Safety and antitumor activity of durvalumab plus tremelimumab in non-small-cell lung cancer: a multicenter, phase 1b study. *Lancet Oncol* 2016; 17: 299-308. *These authors contributed equally to this work.
10. Yushak ML, Han G, Bouberhan S, Epstein L, DiGiovanna MP, Mougalian SS, Sanft TB, Abu-Khalaf MM, Chung GG, Stein SM, **Goldberg SB**, Puztai L, Hofstatter EW. Patient preferences regarding incidental genomic findings discovered during tumor profiling. *Cancer* 2016; 122: 1588-97.
11. Cohen JV, Alomari AK, Vortmeyer AO, Jilaveanu LB, **Goldberg SB**, Mahajan A, Chiang VL, Kluger HM. Melanoma brain metastasis pseudoprogression after pembrolizumab treatment. *Cancer Immunol Res*. 2016; 4(3):179-82.
12. Alomari AK, Cohen J, Vortmeyer AO, Ching A, Gettinger S, **Goldberg S**, Kluger HM, Chiang VL. Possible interaction of anti-PD-1 therapy with the effects of radiosurgery on brain metastases. *Cancer Immunol Res*. 2016; 4(6):481-7.
13. **Goldberg SB**, Gettinger SN, Mahajan A, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. *Lancet Oncol* 2016; 17(7):976-83.
14. Papadimitrakopoulou V, Lee JJ, Wistuba II, Tsao AS, Fossella FV, Kalhor N, Gupta S, Byers LA, Izzo JG, Gettinger SN, **Goldberg SB**, Tang X, Miller VA, Skoulidis F, Gibbons DL, Shen L, Wei C, Diao L, Peng SA, Wang J, Tam AL, Coombes KR, Koo JS, Mauro DJ, Rubin EH, Heymach JV, Hong WK, Herbst RS. The BATTLE-2 study: a biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer. *J Clin Oncol*. 2016; 34: 3638-3647. PMID: 27480147
15. Pirazzoli V, Ayeni D, Meador CB, Sanganahalli BG, Hyder F, de Stanchina E, **Goldberg SB**, Pao W, Politi K. Afatinib plus cetuximab delays resistance compared to single-agent erlotinib or Afatinib in mouse models of TKI-naïve EGFR L858R-induced lung adenocarcinoma. *Clin Cancer Res*. 2016; 22(2):426-35.

16. Lester-Coll NH, Rutter CE, Bledsoe TJ, **Goldberg SB**, Decker RH, Yu JB. Cost-effectiveness of surgery, stereotactic body radiation therapy, and systemic therapy for pulmonary oligometastases. *Int J Radiat Oncol Biol Phys*. 2016 Jun 1;95(2):663-72. doi: 10.1016/j.ijrobp.2016.01.020.
17. Qian JM, Mahajan A, Yu JB, Tsiouris AJ, **Goldberg SB**, Kluger HM, Chiang VL. Comparing available criteria for measuring brain metastasis response to immunotherapy. *J Neurooncol*. 2017 May;132(3):479-485. doi: 10.1007/s11060-017-2398-8. Epub 2017 Mar 8. PMID: 28275886
18. Gettinger S, Choi J, Hastings K, Truini A, Datar I, Sowell R, Wurtz A, Dong W, Cai G, Melnick MA, Du VY, Schlessinger J, **Goldberg SB**, Chiang A, Sanmamed MF, Melero I, Agorreta J, Montuenga LM, Lifton R, Ferrone S, Kavathas P, Rimm DL, Kaech SM, Schalper K, Herbst RS, Politi K. Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. *Cancer Discov*. 2017 Dec;7(12):1420-1435. doi: 10.1158/2159-8290.CD-17-0593. Epub 2017 Oct 12. PMID: 29025772
19. **Goldberg SB**, Narayan A, Kole AJ, Decker RH, Teysir J, Carriero NJ, Lee A, Nemati R, Nath SK, Mane SM, Deng Y, Sukumar N, Zeltermann D, Boffa DJ, Politi K, Gettinger SN, Wilson LD, Herbst RS, Patel AA. Early Assessment of Lung Cancer Immunotherapy Response via Circulating Tumor DNA. *Clin Cancer Res*. 2018 Apr 15;24(8):1872-1880. doi: 10.1158/1078-0432.CCR-17-1341. Epub 2018 Jan 12 PMID: 29330207
20. Gettinger SN, Wurtz A, **Goldberg SB**, Rimm D, Schalper K, Kaech S, Kavathas P, Chiang A, Lilenbaum R, Zeltermann D, Politi K, Herbst RS. Clinical features and management of acquired resistance to PD-1 axis inhibitors in 26 patients with advanced non-small cell lung cancer. *J Thorac Oncol*. 2018 Mar 22. pii: S1556-0864(18)30210-7. doi: 10.1016/j.jtho.2018.03.008. [Epub ahead of print]. PMID: 29578107
21. Robichaux JP, Elamin YY, Tan Z, Carter BW, Zhang S, Liu S, Li S, Chen T, Poteete A, Estrada-Bernal A, Le AT, Truini A, Nilsson MB, Sun H, Roarty E, **Goldberg SB**, Brahmer JR, Altan M, Lu C, Papadimitrakopoulou V, Politi K, Doebele RC, Wong KK, Heymach JV. Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. *Nat Med*. 2018 May;24(5):638-646. doi: 10.1038/s41591-018-0007-9. Epub 2018 Apr 23. PMID: 2968642
22. Uhlig J, Ludwig JM, **Goldberg SB**, Chiang A, Blasberg JD, Kim HS. Survival rates after thermal ablation versus stereotactic radiation therapy for stage 1 non-small cell lung cancer: a national cancer database study. *Radiology*. 2018 Dec;289(3):862-870. doi: 10.1148/radiol.2018180979. PMID 300226453.
23. Siegel J, Totonchy M, Damsky W, Berk-Krauss J, Castiglione F, Sznol M, Petrylak DP, Fischbach N, **Goldberg SB**, Decker RH, Stamatouli AM, Hafez N, Glusac EJ, Tamayko MM, Leventhal JS. Bullous disorders associated with anti-PD-1 and anti-PD-L1 therapy: a retrospective analysis evaluating the clinical and histopathologic features, frequency, and impact on cancer therapy. *J Am Acad Dermatol*. 2018 Dec;79(6):1081-1088. doi: 10.1016/j.jaad.2018.07.008. PMID: 30025829.
24. Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, Perrotti E, Anderson G, Ralabate A, Kluger Y, Wei W, **Goldberg SB***, Jilaveanu LB*. Long-term

survival of patients with melanoma with active brain metastases treated with pembrolizumab on a phase II trial. *J Clin Oncol*. 2019; 37(1):52-60. PMID 30407895.

*These authors contributed equally to this work.

25. Tran TT, Mahajan A, Chiang VL, **Goldberg SB**, Nguyen DX, Jilaveanu LB, Kluger HM. Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy. *J Immunother Cancer*. 2019 Jul 30;7(1):200. doi: 10.1186/s40425-019-0684-z.
26. Hastings K, Yu HA, Wei W, Sanchez-Vega F, DeVeaux M, Choi J, Rizvi H, Lisberg A, Truini A, Lydon CA, Liu Z, Henick BS, Wurtz A, Cai G, Plodkowski AJ, Long NM, Halpenny DF, Killam J, Oliva I, Schultz N, Riely GJ, Arcila ME, Ladanyi M, Zelterman D, Herbst RS, **Goldberg SB**, Awad MM, Garon EB, Gettinger S, Hellmann MD, Politi K. EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer. *Ann Oncol*. 2019 Aug 1;30(8):1311-1320. doi: 10.1093/annonc/mdz141.
27. Truini A, Starrett JH, Stewart TF, Ashtekar KD, Walther Z, Wurtz A, Lu D, Park JH, DeVeaux M, Song X, Gettinger S, Zelterman D, Lemmon MA, **Goldberg SB**, Politi K. The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma. *Clin Cancer Res*. 2019 Nov 1;25(21):6382-6391. doi: 10.1158/1078-0432.CCR-19-0780.
28. Qian JM, Yu JB, Mahajan A, **Goldberg SB**, Kluger HM, Chiang VLS. Frequent use of local therapy underscores need for multidisciplinary care in the management of patients with melanoma brain metastases treated with PD-1 inhibitors. *Int J Radiat Oncol Biol Phys*. 2019 Dec 1;105(5):1113-1118. doi: 10.1016/j.ijrobp.2019.08.053.
29. Gerber D, Infante J, Gordon M, **Goldberg S**, Martin M, Felip E, Martinez Garcia M, Schiller J, Spigel D, Cordova J, Westcott V, Wang Y, Shames D, Choi Y, Kahn R, Dere R, Samineni D, Xu J, Lin K, Wood K, Royer-Joo S, Lemahieu V, Schuth E, Vaze A, Maslyar D, Humke E, Burris H. Phase Ia study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin DNIB0600A in non-small cell lung cancer and platinum-resistant ovarian cancer patients. *Clin Cancer Res*. 2020 Jan 15;26(2):364-372. doi: 10.1158/1078-0432.CCR-18-3965.
30. Ahn MJ, Chiu CH, Cheng Y, Han JY, **Goldberg SB**, Greystoke A, Crawford J, Zhao Y, Huang X, Johnson M, Vishwanathan K, Yates JWT, Brown AP, Mendoza-Naranjo A, Mok T. Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. *J Thorac Oncol*. 2020 Apr;15(4):637-648. doi: 10.1016/j.jtho.2019.12.113
31. Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn MJ, van den Heuvel MM, Cobo M, Vicente D, Smolin A, Moiseyenko V, Antonia SJ, Le Moulec S, Robinet G, Natale R, Schneider J, Shepherd FA, Geater SL, Garon EB, Kim ES, **Goldberg SB**, Nakagawa K, Raja R, Higgs BW, Boothman AM, Zhao L, Scheuring U, Stockman PK, Chand VK, Peters S; MYSTIC Investigators. Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. *JAMA Oncol*. 2020 Apr 9;6(5):661-74. doi: 10.1001/jamaoncol.2020.0237.

32. Starrett JH, Guernet AA, Cuomo ME, Poels KE, van Alderwerelt van Rosenburgh IK, Nagelberg A, Farnsworth D, Price KS, Khan H, Ashtekar KD, Gaefele M, Ayeni D, Stewart TF, Kuhlmann A, Kaech S, Unni AM, Homer R, Lockwood WW, Michor F, **Goldberg SB**, Lemmon MA, Smith PD, Cross DA, Politi K. Drug sensitivity and allele-specificity of first-line osimertinib resistance EGFR mutations. *Cancer Res.* 2020 May 15;80(10):2017-2030. doi: 10.1158/0008-5472.CAN-19-3819.
33. **Goldberg SB**, Schalper KA, Gettinger SN, Mahajan A, Herbst RS, Chiang AC, Lilenbaum R, Wilson FH, Omay SB, Yu JB, Jilaveanu L, Tran T, Pavlik K, Rowen E, Gerrish H, Komlo A, Gupta R, Wyatt H, Ribeiro M, Kluger Y, Zhou G, Wei W, Chiang VL, Kluger HM. Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial. *Lancet Oncol.* 2020 May;21(5):655-663. doi: 10.1016/S1470-2045(20)30111-X.
34. Pathak R, **Goldberg SB**, Canavan M, Herrin J, Hoag JR, Salazar MC, Papageorge M, Ermer T, Boffa DJ. Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. *JAMA Oncol.* 2020 Sep 17;6(11):1-10. doi: 10.1001/jamaoncol.2020.4232. Online ahead of print. PMID: 32940636.
35. Pathak R, De Lima Lopes G, Yu H, Aryal MR, Ji W, Frumento KS, Wallis CJD, Klaassen Z, Park HS, **Goldberg SB**. Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials. *Cancer* 2020 Oct 29. doi: 10.1002/cncr.33269. Online ahead of print. PMID: 33119177
36. **Goldberg SB**, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, Herbst RA, Baumgart MA, Miao J, Moon J, Kelly K, Gandara DR. A randomized trial of afatinib plus cetuximab versus afatinib alone for first-line treatment of EGFR-mutant non-small cell lung cancer: final results from SWOG S1403. *J Clin Oncol.* 2020 Dec 1;38(34):4076-85. doi: 10.1200/JCO.20.01149.
37. Hysell, K., Yusef R., Barakat L, Virata, M, Gan G, Deng, Yan, Perez-Irizarry J, Vega T, **Goldberg SB**, Emu B, Decreased Overall Survival in HIV-Associated Non Small Cell Lung Cancer. *Clinical Lung Cancer.* Published:December 01, 2020 DOI:<https://doi.org/10.1016/j.clcc.2020.11.006>.
38. Petrulli JR, Zheng M, Huang Y, Nabulsi NB, **Goldberg SB**, Contessa JN, Morris ED. Evaluation of quantitative modeling methods in whole-body, dynamic [11C]-erlotinib PET. *Am J Nucl Med Mol Imaging.* 2021 Apr 15;11(2):143-153. eCollection 2021. PMID: 34079641
39. Cheok SK, Narayan A, Arnal-Estape A, Gettinger S, **Goldberg SB**, Kluger HM, Nguyen D, Patel A, Chiang V Tumor DNA Mutations From Intraparenchymal Brain Metastases Are Detectable in CSF. *JCO Precis Oncol.* 2021 Jan 12;5:PO.20.00292. doi: 10.1200/PO.20.00292. eCollection 2021. PMID: 34250381
40. Yu HA, **Goldberg SB**, Le X, Piotrowska Z, Goldman JW, De Langen AJ, Okamoto I, Cho BC, Smith P, Mensi I, Ambrose H, Kraljevic S, Maidment J, Chmielecki J, Li-Sucholeiki X, Doughton G, Patel G, Jewsbury P, Szekeres P, Riess JW Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose

Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clin Lung Cancer. 2021 Jun 25;S1525-7304(21)00157-1. doi: 10.1016/j.clcc.2021.06.006. Online ahead of print. PMID: 34389237

Chapters, Books, and Reviews

41. T. L. Lynch, J.R. Brahmer, S.N. Gettinger, **S.B. Goldberg**, G.J. Riely, L.V. Sequist, A.T. Shaw M.A. Socinski. “Novel Agents in Lung Cancer: Advances in Dual Kinase Inhibitors, Immune Modulation and Maintenance.” 2012. from <http://www.freecme.com/novel-lung-cancer/>
42. **Goldberg, S.B.**, H. Willers, R.S. Heist. “Multidisciplinary Management of Small Cell Lung Cancer.” *Surgical Oncology Clinical N. Am.* 2013;22(2):329-43.
43. Henick B, Herbst RS, **Goldberg S.B.**, “The PD-1 Pathway as a Therapeutic Target to Overcome Immune Escape Mechanisms in Cancer”. *Expert Opinion on Therapeutic Targets*. 2014; 18(12):1407-20. PMID: 25331677.
44. Morgensztern D, Campo MJ, Dahlberg SE, Doebele RC, Garon E, Gerber DE, **Goldberg S.B.**, Hammerman PS, Heist RS, Hensing T, Horn L, Ramalingam SS, Rudin CM, Salgia R, Sequist LV, Shaw AT, Simon GR, Somaiah N, Spigel DR, Wrangle J, Johnson D, Herbst RS, Bunn P, Govindan R. “Molecularly Targeted Therapies in Non-Small-Cell Lung Cancer Annual Update 2014.” *J Thorac Oncol*. 2015 Jan;10(1 Suppl 1):S1-S63. PMID: 25535693
45. Copur MS, Gettinger S, **Goldberg SB**, and Deshpande H. Miscellaneous Chemotherapeutic Agents. In Devita VT, Lawrence TS, and Rosenberg SA (Eds.), *Cancer: Principles & Practice of Oncology*. 10th edition, pp 267-277. Philadelphia, PA: Wolters Kluwer Health, 2015.
46. **Goldberg SB**, Contessa JN, Omay SB, and Chiang V. “Lung Cancer Brain Metastases.” *Cancer J* 2015 Sep-Oct;21(5):398-403.
47. **Goldberg SB**. “PD-1 and PD-L1 Inhibitors: Activity as Single Agents and Potential Biomarkers in Non-Small Cell Lung Cancer. *Am J Hematol Oncol* 2015; 11(9):10-13.
48. **Goldberg SB**, Herbst RS. Progress and Future Directions for the Treatment of Advanced Lung Cancer. *Cancer J*. 2015 Sep-Oct;21(5):365. doi: 10.1097/PPO.0000000000000152.
49. **Goldberg SB**. “Principles of Immunotherapy.” In Govindan R and Morgensztern D (Eds.), *DeVita, Hellman, and Rosenberg’s Cancer: Principles & Practice of Oncology Review*. 4th edition, pp 89-96. Philadelphia, PA: Wolters Kluwer Health, 2016.
50. Valiente M, Ahluwalia MS, Boire A, Brastianos PK, **Goldberg SB**, Lee EQ, Le Rhun E, Preusser M, Winkler F, Soffiatti R. The Evolving Landscape of Brain Metastasis. *Trends Cancer*. 2018 Mar;4(3):176-196. doi: 10.1016/j.trecan.2018.01.003. Epub 2018 Feb 21. Review. PMID: 29506669
51. **Goldberg SB**, Patel AA. Monitoring immunotherapy outcomes with circulating tumor DNA. *Immunotherapy*. 2018 Sep;10(12):1023-1025. doi: 10.2217/imt-2018-0084.

52. Remon J, Passiglia F, Ahn MJ, Barlesi F, Forde PM, Garon EB, Gettinger S, **Goldberg SB**, Herbst RS, Horn L, Kubota K, Lu S, Mezquita L, Paz-Ares L, Popat S, Schalper KA, Skoulidis F, Reck M, Adjei AA, Scagliotti GV. Immune checkpoint inhibitors in thoracic malignancies: Review of the existing evidence by an IASLC expert panel and recommendations. *J Thorac Oncol*. 2020 Jun;15(6):914-947. doi: 10.1016/j.jtho.2020.03.006.
53. Eguren-Santamaria I, Sanmamed MF, **Goldberg SB**, Kluger HM, Idoate MA, Lu BY, Corral J, Schalper KA, Herbst RS, Gil-Bazo I. PD-1/PD-L1 blockers in NSCLC brain metastases: challenging paradigms and clinical practice. *Clin Cancer Res*. 2020 Aug 15;26(16):4186-4197. doi: 10.1158/1078-0432.
54. Grant MJ, Herbst RS, **Goldberg SB**. Selecting the optimal immunotherapy regimen in driver-negative metastatic NSCLC. *Nat Rev Clin Oncol*. 2021 Jun 24. doi: 10.1038/s41571-021-00520-1. Online ahead of print. PMID: 34168333.

Invited Editorials, Commentaries and Series

55. **Goldberg, S.B.**, J. Schlessinger, J.L. Boyer, R.S. Herbst. A step towards treating KRAS-mutant NSCLC. *Lancet Oncology*, 2013, 14(1), pp. 3-5.
56. Ayeni D, Politi K, **Goldberg SB**. Emerging Agents and New Mutations in EGFR-Mutant Lung Cancer. *Clin Cancer Res*. 2015 Sep 1;21(17):3818-20.
57. Stewart, TF, **Goldberg, SB**. Immunotherapy Plus Chemotherapy in Non-Small Cell Lung Cancer: Despite the Failure of Ipilimumab, Guarded Optimism Persists. *ASCO Post*, 2017 Dec 10.
58. Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, **Goldberg SB**. Introduction to the Yale Precision Medicine Tumor Board. *Lancet Oncol*. 2018 Jan;19(1):19-20. doi: 10.1016/S1470-2045(17)30919-1 PMID: 29304351
59. Cecchini M, Walther Z, Sklar JL, Bindra RS, Petrylak DP, Eder JP, **Goldberg SB**. Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes *Lancet Oncol*. 2018 Jan;19(1):23-24. doi: 10.1016/S1470-2045(17)30916-6.
60. Stewart T, Finberg KE, Walther Z, Sklar JL, Hafez N, Eder JP, Anderson KS, Wilson F, **Goldberg SB**. Yale Cancer Center Precision Medicine Tumor Board: one tumor, multiple targets. *Lancet Oncol*. 2018 Dec;19(12):1567-1568.
61. **Goldberg SB**, Herbst RS. Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer? *Cancer*. 2018 Dec;124(24):4592-4596. PMID 30383887.
62. Kluger HM, Margolin KA, Davies MA, Long GV, Tawbi HA, **Goldberg SB**, Chiang VL. Reply to A. Shinde et al. *J Clin Oncol*. 2019 Apr 20;37(12):1031-1032. doi: 10.1200/JCO.18.02463.
63. Collier EF, Herbst RS, **Goldberg SB**. KEYNOTE-010: Long-term outcomes and results of retreatment. *IASLC Lung Cancer News*. 2019 August 14.

64. Hafez N, Walther Z, Eder JP, Sklar JL, Gettinger SN, Finberg KE, **Goldberg SB**. Yale Cancer Center Precision Medicine Tumor Board: New Technology, New Drugs, and the Value of Repeat Testing. *Lancet Oncol*. 2020 Mar;21(3):343-344.
65. **Goldberg SB**, Pembrolizumab Is Active in Lung Cancer Brain Metastases. *IASLC Lung Cancer News, Journal Radar*. 2020 December 14.
66. **Goldberg SB**, Herbst, Roy S. Introduction by the Guest Editors, *The Cancer Journal*. 2020 November 12;26(6):471-472. doi: 10.1097/PPO.0000000000000487.
67. Collier E, **Goldberg SB**, CM227/CM9-LA: evidence supporting ipilimumab-based immunotherapy in the first-line treatment of metastatic NSCLC, *Precision Cancer Medicine*. 2020 December 30. doi: 10.21037/pcm-2020-mnslc-04.
68. **Goldberg SB**, Herbst RS. Introduction by the Guest Editors. *Cancer J*. 2020 Nov/Dec;26(6):471-472. doi: 10.1097/PPO.0000000000000487. PMID: 33298717.
69. Gibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, **Goldberg SB**. Gibson JA, Finberg KE, Nalbantoglu I, Cecchini M, Ganzak A, Walther Z, Sklar JL, Eder JP, **Goldberg SB**, Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment plan. *Lancet Oncol*. 2021 Mar;22(3):306-307. doi: 10.1016/S1470-2045(20)30683-5. PMID: 33662283.